Listed

ENDRA Life Sciences Inc.: Form 10-Q for the period ended Mar 31, 2020

Filed with the SEC on May 14, 2020 and accepted by EDGAR at May 14, 2020, 17:24 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-01-01 to 2020-03-31$1.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-01-01 to 2020-03-31−$3.1mus-gaap:OperatingIncomeLoss
Income tax3 months2020-01-01 to 2020-03-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-01-01 to 2020-03-31−$3.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-01-01 to 2020-03-31−$0.29us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2020-01-01 to 2020-03-31−$3.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2020-01-01 to 2020-03-31$22.4kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2020-01-01 to 2020-03-31$34.1kus-gaap:PaymentsOfDividendsCommonStock
Cash and equivalentsAt period end2020-03-31$3.1mus-gaap:Cash
Current assetsAt period end2020-03-31$3.8mus-gaap:AssetsCurrent
Total assetsAt period end2020-03-31$4.4mus-gaap:Assets
Current liabilitiesAt period end2020-03-31$1.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-03-31$1.9mus-gaap:Liabilities
Shareholders' equityAt period end2020-03-31$2.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001654954-20-005509. Last ingested by Listed: Nov 10, 2026, 17:03 ET. Listed shows no prices and gives no investment advice.